Siguazodan (SKF 94836) 是一种有效的,选择性的,口服活性的磷酸二酯酶 III (PDE-III) 抑制剂,IC50 为 117 nM。Siguazodan 可增加完整血小板中 cAMP 的积累,EC50 为 18.88 μM。Siguazodan 还抑制苯肾上腺素诱导的 5-HT 释放,IC50 值为 4.2 μM。 Siguazodan (SKF 94836) is a potent, selective and orally active phosphodiesterase III (PDE-III) inhibitor with an IC50 of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC50 of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC50 value of 4.2 μM.
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Siguazodan
Dangerous GoodsCAS number:115344-47-3 molecular formula:C14H16N6O
overview
compound introduction
Specs
| Chinese alias | N-氰基-N'-甲基-N''-[4-(1,4,5,6-四氢-4-甲基-6-氧代-3-哒嗪基)苯基]胍 | ||
| English alias | SR-01000075284-1 | AKOS024456417 | Dicarbethoxymethane | SkF94836 | SKF-94836 | Diaethylacetal | Guanidine, N-cyano-N'-methyl-N''-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]- | GLXC-26081 | HMS2090J18 | NCGC00025032-04 | sec-Butyl ethanoat | ||
| CAS number | 115344-47-3 | molecular formula | C14H16N6O |
| molecular weight | 284.32 g/mol | Exact mass | - |
| PSA | 102.000 Ų | logp | 1.3 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
pictogram:
GHS07
Signal word:
Warning
Hazard Statement:
H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激
Statement of Preventive Measures:
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P302+P352: 如皮肤沾染:用水充分清洗。 P321: 特殊处理(请参阅此标签上的...)。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P264: 处理后要彻底洗手。 P271: 仅在室外或通风良好的地方使用。 P304+P340: 如误吸入:将人转移
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS





